Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Vaginitis Therapeutics Market by Type (Anti-fungal, Anti-bacterial, Hormone, Other), By Application (Atrophic Vaginitis, Bacterial Vaginosis, Trichomonas Vaginalis, Candida Albicans, Other) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Vaginitis Therapeutics Market by Type (Anti-fungal, Anti-bacterial, Hormone, Other), By Application (Atrophic Vaginitis, Bacterial Vaginosis, Trichomonas Vaginalis, Candida Albicans, Other) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 133813 3300 Pharma & Healthcare 377 247 Pages 4.6 (36)

Market Overview:

The global vaginitis therapeutics market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of vaginitis, rising awareness about available treatments, and growing demand for novel therapies. Based on type, the global vaginitis therapeutics market is segmented into anti-fungal, anti-bacterial, hormone therapy, and other therapies. The anti-fungal therapy segment is expected to account for the largest share of the global vaginitis therapeutics market in 2018. This segment is projected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030 due to increasing incidence of fungal infections worldwide. Based on application, the global vaginitis therapeutics market is divided into atrophic vaginitis, bacterial vaginosis (BV), trichomoniasis vaginalis (TV), candidiasis (thrush), and other applications.

Global Vaginitis Therapeutics Industry Outlook

Product Definition:

Vaginitis is a condition that results in inflammation of the vagina. Symptoms may include discharge, itching, and burning. Vaginitis can be caused by bacteria, viruses, or other organisms such as parasites. It can also be caused by chemicals irritants or allergic reactions. Treatment depends on the cause of the vaginitis.


Anti-fungal is a drug or medication that prevents fungal infections. Fungi are organisms that reproduce by budding off spores, which may cause infection in humans and animals. The most common types of fungi are molds, yeasts, and mushrooms; the most common mold is called asmallothecium fungus or white powdery mildew.


Antibacterial is a drug that prevents the growth of bacteria. Some antibacterial drugs include cephalosporin, penicillin, macrolide antibiotics and tetracycline. Antibiotics are used to treat bacterial vaginosis (BV), urinary tract infections (UTI) and skin infections including cellulitis, furunculosis, necrotizing infection or boil.

Application Insights:

Based on the application, the global market is segmented into atrophic vaginitis, bacterial vaginosis (BV), trichomoniasis vaginalis (T. vaginalis), Candida albicans (C. albicans), and others. Atrophic vaginitis held the largest share in 2017 due to increasing prevalence of aging and post-menopausal women are more susceptible to this condition than men. Bacterial vaginosis is expected to be the fastest growing segment over forecast period owing to rising awareness about maintaining good hygiene and appropriate management of sex life among women after marriage as well as before marriage period which may result in increased usage of these products by them during this time frame.

Regional Analysis:

North America dominated the global market in 2017. This can be attributed to the high prevalence of BV, CAUTIs, and yeast infections among women in this region. According to a study published by National Institute of Health (NIH), around 25% - 40% of all women are estimated to be affected with at least one form of vaginal infection during their lifetime. Furthermore, increasing awareness about these infections and availability of effective treatment methods are some other factors contributing toward regional growth.

Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income levels and growing population especially in India & China & Japan which will result into an increase in incidence rates for various vaginal diseases including bacterial vaginosis (BV), trichomoniasis, candidiasis etc., over this period.

Growth Factors:

  • Increasing incidence of vaginitis
  • Rising awareness about the available treatment options for vaginitis
  • Growing demand for effective and safe over-the-counter (OTC) treatments for vaginitis
  • Proliferation of online resources and support groups devoted to helping women with vaginitis 5. Emerging therapies and products that could offer better outcomes and fewer side effects than currently available treatments

Scope Of The Report

Report Attributes

Report Details

Report Title

Vaginitis Therapeutics Market Research Report

By Type

Anti-fungal, Anti-bacterial, Hormone, Other

By Application

Atrophic Vaginitis, Bacterial Vaginosis, Trichomonas Vaginalis, Candida Albicans, Other

By Companies

Bayer AG, Lupin Pharmaceuticals, Inc, Merck & Co, Mission Pharmacal Company, Novartis AG, Pfizer, Inc, Symbiomix Therapeutics, Inc

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year


Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year


Number of Pages


Number of Tables & Figures


Customization Available

Yes, the report can be customized as per your need.

Global Vaginitis Therapeutics Market Report Segments:

The global Vaginitis Therapeutics market is segmented on the basis of:


Anti-fungal, Anti-bacterial, Hormone, Other

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.


Atrophic Vaginitis, Bacterial Vaginosis, Trichomonas Vaginalis, Candida Albicans, Other

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Bayer AG
  2. Lupin Pharmaceuticals, Inc
  3. Merck & Co
  4. Mission Pharmacal Company
  5. Novartis AG
  6. Pfizer, Inc
  7. Symbiomix Therapeutics, Inc

Global Vaginitis Therapeutics Market Overview

Highlights of The Vaginitis Therapeutics Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Anti-fungal
    2. Anti-bacterial
    3. Hormone
    4. Other
  1. By Application:

    1. Atrophic Vaginitis
    2. Bacterial Vaginosis
    3. Trichomonas Vaginalis
    4. Candida Albicans
    5. Other
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Vaginitis Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Vaginitis Therapeutics Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?

Vaginitis Therapeutics is a clinical stage biotechnology company focused on the development of novel therapeutics for women's health. The Company's lead product candidate, V-971, is an investigational vaginal gel formulation that is designed to improve symptoms of vaginitis.

Some of the key players operating in the vaginitis therapeutics market are Bayer AG, Lupin Pharmaceuticals, Inc, Merck & Co, Mission Pharmacal Company, Novartis AG, Pfizer, Inc, Symbiomix Therapeutics, Inc.

The vaginitis therapeutics market is expected to register a CAGR of 5.5%.

1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Vaginitis Therapeutics Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Vaginitis Therapeutics Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Vaginitis Therapeutics Market - Supply Chain
   4.5. Global Vaginitis Therapeutics Market Forecast
      4.5.1. Vaginitis Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Vaginitis Therapeutics Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Vaginitis Therapeutics Market Absolute $ Opportunity

5. Global Vaginitis Therapeutics Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Vaginitis Therapeutics Market Size and Volume Forecast by Type
      5.3.1. Anti-fungal
      5.3.2. Anti-bacterial
      5.3.3. Hormone
      5.3.4. Other
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Vaginitis Therapeutics Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Vaginitis Therapeutics Market Size and Volume Forecast by Application
      6.3.1. Atrophic Vaginitis
      6.3.2. Bacterial Vaginosis
      6.3.3. Trichomonas Vaginalis
      6.3.4. Candida Albicans
      6.3.5. Other
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Vaginitis Therapeutics Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Vaginitis Therapeutics Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Vaginitis Therapeutics Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Vaginitis Therapeutics Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Vaginitis Therapeutics Demand Share Forecast, 2019-2029

9. North America Vaginitis Therapeutics Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Vaginitis Therapeutics Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Vaginitis Therapeutics Market Size and Volume Forecast by Application
      9.4.1. Atrophic Vaginitis
      9.4.2. Bacterial Vaginosis
      9.4.3. Trichomonas Vaginalis
      9.4.4. Candida Albicans
      9.4.5. Other
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Vaginitis Therapeutics Market Size and Volume Forecast by Type
      9.7.1. Anti-fungal
      9.7.2. Anti-bacterial
      9.7.3. Hormone
      9.7.4. Other
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Vaginitis Therapeutics Demand Share Forecast, 2019-2029

10. Latin America Vaginitis Therapeutics Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Vaginitis Therapeutics Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Vaginitis Therapeutics Market Size and Volume Forecast by Application
      10.4.1. Atrophic Vaginitis
      10.4.2. Bacterial Vaginosis
      10.4.3. Trichomonas Vaginalis
      10.4.4. Candida Albicans
      10.4.5. Other
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Vaginitis Therapeutics Market Size and Volume Forecast by Type
      10.7.1. Anti-fungal
      10.7.2. Anti-bacterial
      10.7.3. Hormone
      10.7.4. Other
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Vaginitis Therapeutics Demand Share Forecast, 2019-2029

11. Europe Vaginitis Therapeutics Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Vaginitis Therapeutics Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Vaginitis Therapeutics Market Size and Volume Forecast by Application
      11.4.1. Atrophic Vaginitis
      11.4.2. Bacterial Vaginosis
      11.4.3. Trichomonas Vaginalis
      11.4.4. Candida Albicans
      11.4.5. Other
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Vaginitis Therapeutics Market Size and Volume Forecast by Type
      11.7.1. Anti-fungal
      11.7.2. Anti-bacterial
      11.7.3. Hormone
      11.7.4. Other
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Vaginitis Therapeutics Demand Share, 2019-2029

12. Asia Pacific Vaginitis Therapeutics Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Vaginitis Therapeutics Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Vaginitis Therapeutics Market Size and Volume Forecast by Application
      12.4.1. Atrophic Vaginitis
      12.4.2. Bacterial Vaginosis
      12.4.3. Trichomonas Vaginalis
      12.4.4. Candida Albicans
      12.4.5. Other
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Vaginitis Therapeutics Market Size and Volume Forecast by Type
      12.7.1. Anti-fungal
      12.7.2. Anti-bacterial
      12.7.3. Hormone
      12.7.4. Other
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Vaginitis Therapeutics Demand Share, 2019-2029

13. Middle East & Africa Vaginitis Therapeutics Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Vaginitis Therapeutics Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Vaginitis Therapeutics Market Size and Volume Forecast by Application
      13.4.1. Atrophic Vaginitis
      13.4.2. Bacterial Vaginosis
      13.4.3. Trichomonas Vaginalis
      13.4.4. Candida Albicans
      13.4.5. Other
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Vaginitis Therapeutics Market Size and Volume Forecast by Type
      13.7.1. Anti-fungal
      13.7.2. Anti-bacterial
      13.7.3. Hormone
      13.7.4. Other
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Vaginitis Therapeutics Demand Share, 2019-2029

14. Competition Landscape
   14.1. Global Vaginitis Therapeutics Market: Market Share Analysis
   14.2. Vaginitis Therapeutics Distributors and Customers
   14.3. Vaginitis Therapeutics Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Bayer AG Overview Financials Developments Strategic Outlook
      14.4.2. Lupin Pharmaceuticals, Inc Overview Financials Developments Strategic Outlook
      14.4.3. Merck & Co Overview Financials Developments Strategic Outlook
      14.4.4. Mission Pharmacal Company Overview Financials Developments Strategic Outlook
      14.4.5. Novartis AG Overview Financials Developments Strategic Outlook
      14.4.6. Pfizer, Inc Overview Financials Developments Strategic Outlook
      14.4.7. Symbiomix Therapeutics, Inc Overview Financials Developments Strategic Outlook
      14.4.8. COMPANY8 Overview Financials Developments Strategic Outlook
      14.4.9. COMPANY9 Overview Financials Developments Strategic Outlook
      14.4.10. COMPANY 10 Overview Financials Developments Strategic Outlook
      14.4.11. COMPANY 11 Overview Financials Developments Strategic Outlook
      14.4.12. COMPANY 12 Overview Financials Developments Strategic Outlook
      14.4.13. COMPANY 13 Overview Financials Developments Strategic Outlook
      14.4.14. COMPANY 14 Overview Financials Developments Strategic Outlook
      14.4.15. COMPANY 15 Overview Financials Developments Strategic Outlook
      14.4.16. COMPANY 16 Overview Financials Developments Strategic Outlook
      14.4.17. COMPANY 17 Overview Financials Developments Strategic Outlook
      14.4.18. COMPANY 18 Overview Financials Developments Strategic Outlook
      14.4.19. COMPANY 19 Overview Financials Developments Strategic Outlook
      14.4.20. COMPANY 20 Overview Financials Developments Strategic Outlook

Our Trusted Clients

Contact Us